Overview
Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist sharing 94% sequence homology with native human GLP-1. It is chemically modified to include a C18 fatty diacid side chain and specific amino acid substitutions that confer resistance to dipeptidyl peptidase-4 (DPP-4) enzymatic degradation, making it a stable and reproducible tool compound for controlled laboratory research applications.
Scientific investigation of Semaglutide in controlled experimental settings focuses on its biochemical interactions with pancreatic beta-cells, insulin signaling pathways, and central nervous system receptors involved in appetite regulation pathway research. All applications are strictly confined to in-vitro and in-vivo animal research contexts and do not imply clinical, cosmetic, or therapeutic use.
Biochemical Characteristics
- Peptide Sequence: Modified GLP-1 (7-37) backbone with acylation
- Sequence: His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEA-AEEA-γ-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly
- Molecular Formula: C₁₈₇H₂₉₁N₄₅O₅₉
- Molecular Weight: 4,113.58 g/mol
- PubChem CID: 56843331
- CAS Number: 910463-68-2
Semaglutide is a modified 31-amino acid peptide incorporating critical structural modifications including substitution of Alpha-aminoisobutyric acid (Aib) at position 8 to prevent enzymatic degradation, and acylation of the lysine residue at position 26 with a spacer and C18 fatty diacid chain. This fatty acid moiety promotes non-covalent binding to plasma albumin, significantly extending the molecule's stability in experimental environments and making it a valuable tool compound for chronic exposure studies in controlled laboratory models.
Biochemical analyses demonstrate that Semaglutide exhibits high affinity and selectivity for the GLP-1 receptor. Upon binding in experimental systems, it activates downstream signaling cascades analogous to the native ligand but with a substantially prolonged half-life profile.
Research Applications
Semaglutide is utilized in laboratory research to investigate glucose homeostasis pathway dynamics, insulin secretion mechanisms, and lipid metabolism endpoints. Experimental systems include:
- Diet-induced obesity (DIO) murine research models
- Pancreatic islet cell culture systems
- Gastric emptying rate measurement assays
- Neuroinflammation and neuroprotection pathway research in rodent neurodegeneration models
- Cognitive function marker assessment in controlled preclinical paradigms
- Hepatic steatosis reduction pathway investigation
- Cardiovascular marker modulation under controlled experimental conditions
- Comparative incretin mimetic benchmark studies in preclinical research systems
Pathway & Mechanistic Context
Mechanistic studies document Semaglutide as a specific ligand for the GLP-1 receptor in experimental systems. Receptor binding initiates a signaling cascade involving:
- Adenylyl cyclase activation
- Cyclic adenosine monophosphate (cAMP) accumulation
- Protein kinase A (PKA) activation and downstream transcriptional activity
Gene-expression analyses further demonstrate that Semaglutide influences transcriptional networks associated with insulin gene transcription and beta-cell proliferation markers in controlled laboratory settings. Additional mechanistic research areas include:
- Adipose tissue pathway modeling — lipolysis and energy uptake pathway modulation
- Central nervous system receptor activation research — hypothalamic and brainstem receptor interaction studies
- Insulin sensitivity pathway dynamics in defined experimental models
- Lipid metabolism and hepatic signaling pathway investigation
Preclinical Research Summary
Preclinical investigations of Semaglutide include extensive in-vivo studies across rodent and non-human primate research models. Commonly evaluated experimental endpoints include:
- Body weight trajectory and composition endpoint assessments
- Glycemic regulation parameters including HbA1c-equivalent markers
- Pancreatic beta-cell mass preservation indicators
- Food intake regulation pathway endpoints
- Gastric emptying dynamics under defined experimental conditions
- Insulin sensitivity markers in controlled research models
- Hepatic steatosis and liver function marker assessments
- Cardiovascular parameter endpoint modeling
Semaglutide is also frequently utilized as a benchmark reference compound in comparative studies evaluating novel incretin mimetics in preclinical research systems. All findings are presented exclusively as laboratory observations and do not imply clinical or therapeutic outcomes of any kind.
Form & Analytical Testing
Semaglutide is supplied as a synthetic research-grade peptide for controlled laboratory workflows. Product identity and purity are confirmed using:
- HPLC — purity profiling and lot consistency
- Mass Spectrometry (MS) — molecular identity confirmation
Purity & Quality
- ≥99% Purity — HPLC Verified
- Independently tested by accredited third-party laboratory
- Certificate of Analysis (CoA) available for every batch
Research Use Only (RUO) Notice
All products are furnished strictly for in-vitro laboratory research use only. These materials are not medicines or drugs and have not been evaluated or approved by the U.S. Food and Drug Administration (FDA) to diagnose, treat, cure, or prevent any disease or medical condition. Introduction into humans or animals is strictly prohibited. Not for human, medical, diagnostic, or veterinary use.
